M Eric Gershwin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/117397/publications.pdf

Version: 2024-02-01

236 papers 14,389 citations

69 h-index 109 g-index

238 all docs

238 docs citations

times ranked

238

12609 citing authors

#	Article	IF	CITATIONS
1	Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut, 2022, 71, 899-909.	6.1	51
2	Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review. Clinical Reviews in Allergy and Immunology, 2022, 62, 292-300.	2.9	8
3	E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants. Hepatology, 2022, 75, 266-279.	3.6	18
4	Increased sensitivity of gp 210 autoantibody detection using a newly designed gp 210 antigen. Journal of Immunological Methods, $2022,501,113211.$	0.6	1
5	An update on novel pharmacological agents for primary sclerosing cholangitis. Expert Opinion on Therapeutic Targets, 2022, 26, 69-77.	1.5	5
6	Genomeâ€wide metaâ€analysis identifies susceptibility loci for autoimmune hepatitis type 1. Hepatology, 2022, 76, 564-575.	3.6	11
7	Mushrooms and immunity. Journal of Autoimmunity, 2021, 117, 102576.	3.0	38
8	Ehlers-Danlos Syndrome: Immunologic contrasts and connective tissue comparisons. Journal of Translational Autoimmunity, 2021, 4, 100077.	2.0	9
9	Complex regional pain syndrome – Autoimmune or functional neurologic syndrome. Journal of Translational Autoimmunity, 2021, 4, 100080.	2.0	9
10	The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. Journal of Autoimmunity, 2021, 117, 102592.	3.0	72
11	Antibody glycosylation in autoimmune diseases. Autoimmunity Reviews, 2021, 20, 102804.	2.5	26
12	The Clinical Significance of Hepatic CD69+CD103+CD8+ Residentâ€Memory T Cells in Autoimmune Hepatitis. Hepatology, 2021, 74, 847-863.	3.6	30
13	Transcriptome landscape of double negative T cells by single-cell RNA sequencing. Journal of Autoimmunity, 2021, 121, 102653.	3.0	20
14	Enoxacin Upâ€Regulates MicroRNA Biogenesis and Downâ€Regulates Cytotoxic CD8 T ell Function in Autoimmune Cholangitis. Hepatology, 2021, 74, 835-846.	3.6	11
15	Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives. Expert Review of Clinical Immunology, 2021, 17, 933-936.	1.3	5
16	Interleukin 23 Produced by Hepatic Monocyte-Derived Macrophages Is Essential for the Development of Murine Primary Biliary Cholangitis. Frontiers in Immunology, 2021, 12, 718841.	2.2	8
17	Characterization of Organ-Specific Regulatory B Cells Using Single-Cell RNA Sequencing. Frontiers in Immunology, 2021, 12, 711980.	2.2	10
18	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. Journal of Experimental Medicine, 2021, 218, .	4.2	20

#	Article	IF	CITATIONS
19	The myristoylated alanine-rich C-kinase substrates (MARCKS): A membrane-anchored mediator of the cell function. Autoimmunity Reviews, 2021, 20, 102942.	2.5	21
20	Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis. Gut Microbes, 2021, 13, 1946366.	4.3	25
21	IFN \hat{I}^3 Is a Key Link between Obesity and Th1-Mediated AutoImmune Diseases. International Journal of Molecular Sciences, 2021, 22, 208.	1.8	11
22	Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis. Clinical Reviews in Allergy and Immunology, 2020, 58, 25-38.	2.9	86
23	Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2020, 58, 134-149.	2.9	49
24	Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends. Clinical Reviews in Allergy and Immunology, 2020, 59, 175-194.	2.9	23
25	Ebola virus disease: An emerging and re-emerging viral threat. Journal of Autoimmunity, 2020, 106, 102375.	3.0	79
26	An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24957-24963.	3.3	18
27	Replication study and meta-analysis indicate a suggestive association of RUNX3 locus with primary biliary cholangitis. Immunogenetics, 2020, 72, 467-474.	1.2	0
28	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. Journal of Autoimmunity, 2020, 114, 102506.	3.0	248
29	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. Journal of Autoimmunity, 2020, 113, 102503.	3.0	5
30	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. Journal of Autoimmunity, 2020, 109, 102442.	3.0	104
31	The use of biologics in the treatment of autoimmune liver disease. Expert Opinion on Investigational Drugs, 2020, 29, 385-398.	1.9	8
32	Multi-omics: Differential expression of IFN- \hat{l}^3 results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseases. Journal of Autoimmunity, 2020, 111, 102436.	3.0	25
33	Bystander activation and autoimmunity. Journal of Autoimmunity, 2019, 103, 102301.	3.0	127
34	DNGR1-mediated deletion of A20/Tnfaip3 in dendritic cells alters T and B-cell homeostasis and promotes autoimmune liver pathology. Journal of Autoimmunity, 2019, 102, 167-178.	3.0	14
35	Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in earlyâ€stage primary biliary cholangitis. FASEB Journal, 2019, 33, 10269-10279.	0.2	32
36	Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis. Journal of Autoimmunity, 2019, 103, 102293.	3.0	21

#	Article	IF	CITATIONS
37	The Myth of Mycotoxins and Mold Injury. Clinical Reviews in Allergy and Immunology, 2019, 57, 449-455.	2.9	11
38	Exosomal microRNA in autoimmunity. Cellular and Molecular Immunology, 2019, 16, 932-934.	4.8	29
39	Immunodeficiency and Autoimmunity: The goals of the Journal of Translational Autoimmunity. Journal of Translational Autoimmunity, 2019, 1, 100001.	2.0	1
40	Unmet needs in autoimmune liver diseases. Journal of Digestive Diseases, 2019, 20, 327-330.	0.7	0
41	CTHRC1 expression in primary biliary cholangitis. Journal of Digestive Diseases, 2019, 20, 371-376.	0.7	7
42	Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. Journal of Autoimmunity, 2019, 102, 8-37.	3.0	52
43	Sex and autoimmunity: proposed mechanisms of disease onset and severity. Expert Review of Clinical Immunology, 2019, 15, 607-615.	1.3	19
44	Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. Journal of Autoimmunity, 2019, 101, 26-34.	3.0	40
45	Proteomics in Primary Biliary Cholangitis. Methods in Molecular Biology, 2019, 1981, 163-173.	0.4	1
46	Primary immunodeficiency and autoimmunity: A comprehensive review. Journal of Autoimmunity, 2019, 99, 52-72.	3.0	122
47	The clinical implications of selective IgA deficiency. Journal of Translational Autoimmunity, 2019, 2, 100025.	2.0	37
48	Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1175-1182.e2.	2.4	10
49	Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans. Archives of Medical Science, 2018, 14, 930-940.	0.4	3
50	The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7. Journal of Autoimmunity, 2018, 90, 64-75.	3.0	50
51	The immunotherapy of Guillain-Barré syndrome. Expert Opinion on Biological Therapy, 2018, 18, 619-631.	1.4	11
52	Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cellular and Molecular Immunology, 2018, 15, 547-562.	4.8	105
53	Proteomic analysis reveals distinctive protein profiles involved in CD8+ T cell-mediated murine autoimmune cholangitis. Cellular and Molecular Immunology, 2018, 15, 756-767.	4.8	9
54	Comprehensive review of autoantibodies in patients with hyper-lgM syndrome. Cellular and Molecular Immunology, 2018, 15, 610-617.	4.8	12

#	Article	IF	CITATIONS
55	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 282-294.	2.9	36
56	Myeloid Cells and Chronic Liver Disease: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 307-317.	2.9	6
57	The long and latent road to autoimmunity. Cellular and Molecular Immunology, 2018, 15, 543-546.	4.8	7
58	Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut, 2018, 67, 534-541.	6.1	330
59	Long noncoding RNA lncKdm2b: A critical player in the maintenance of group 3 innate lymphoid cells. Cellular and Molecular Immunology, 2018, 15, 5-7.	4.8	6
60	How the biliary tree maintains immune tolerance?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1367-1373.	1.8	13
61	The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sexâ€biased autoimmunity. Hepatology, 2018, 67, 1408-1419.	3.6	45
62	The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). Autoimmunity Reviews, 2018, 17, 78-85.	2.5	62
63	A Novel $\langle i \rangle$ Pkhd1 $\langle i \rangle$ Mutation Interacts with the Nonobese Diabetic Genetic Background To Cause Autoimmune Cholangitis. Journal of Immunology, 2018, 200, 147-162.	0.4	10
64	Tick-borne diseases and autoimmunity: A comprehensive review. Journal of Autoimmunity, 2018, 88, 21-42.	3.0	12
65	Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis. Hepatology, 2018, 68, 166-171.	3.6	18
66	A functional characteristic of cysteineâ€rich protein 61: Modulation of myeloidâ€derived suppressor cells in liver inflammation. Hepatology, 2018, 67, 232-246.	3.6	39
67	Molecular mimicry and autoimmunity. Journal of Autoimmunity, 2018, 95, 100-123.	3.0	353
68	Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and Fcl3R-Expressing Mice. Frontiers in Immunology, 2018, 9, 2534.	2.2	9
69	Mucosal-Associated Invariant T Cells Improve Nonalcoholic Fatty Liver Disease Through Regulating Macrophage Polarization. Frontiers in Immunology, 2018, 9, 1994.	2.2	72
70	The Immunobiology of Receptor Activator for Nuclear Factor Kappa B Ligand and Myeloidâ€Derived Suppressor Cell Activation in Immunoglobulin G4–Related Sclerosing Cholangitis. Hepatology, 2018, 68, 1922-1936.	3.6	14
71	Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice. Journal of Autoimmunity, 2018, 91, 83-96.	3.0	14
72	Safety issues and recommendations for successful pregnancy outcome in systemic lupus erythematosus. Journal of Autoimmunity, 2018, 93, 16-23.	3.0	35

#	Article	IF	Citations
73	The CXC Chemokine Receptor 3 Inhibits Autoimmune Cholangitis via CD8+ T Cells but Promotes Colitis via CD4+ T Cells. Frontiers in Immunology, 2018, 9, 1090.	2.2	12
74	The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review. Clinical Reviews in Allergy and Immunology, 2017, 52, 58-70.	2.9	41
75	The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cellular and Molecular Immunology, 2017, 14, 276-284.	4.8	51
76	The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology, 2017, 65, 1670-1682.	3.6	33
77	A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. Journal of Autoimmunity, 2017, 77, 123-138.	3.0	65
78	A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nature Communications, 2017, 8, 14828.	5.8	102
79	Original antigenic sin: A comprehensive review. Journal of Autoimmunity, 2017, 83, 12-21.	3.0	161
80	Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics. Hepatology, 2017, 66, 885-895.	3.6	25
81	Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone. Autoimmunity Reviews, 2017, 16, 875-882.	2.5	17
82	Finding the cure for primary biliary cholangitis – Still waiting. Liver International, 2017, 37, 500-502.	1.9	21
83	Mold and Human Health: a Reality Check. Clinical Reviews in Allergy and Immunology, 2017, 52, 305-322.	2.9	43
84	From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. Expert Review of Clinical Immunology, 2017, 13, 1121-1131.	1.3	12
85	Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. Journal of Autoimmunity, 2017, 83, 95-112.	3.0	108
86	Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmunity Reviews, 2017, 16, 885-896.	2.5	158
87	Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review. Rheumatology and Therapy, 2017, 4, 263-279.	1.1	37
88	Primary biliary cholangitis: a comprehensive overview. Hepatology International, 2017, 11, 485-499.	1.9	82
89	Trichloroethylene exposure reduces liver injury in a mouse model of primary biliary cholangitis. Toxicological Sciences, 2017, 156, kfw264.	1.4	5
90	The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. Journal of Autoimmunity, 2016, 74, 118-138.	3.0	154

#	Article	IF	CITATIONS
91	Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. Autoimmunity Reviews, 2016, 15, 870-876.	2.5	32
92	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proofâ€ofâ€concept study. Hepatology, 2016, 64, 189-199.	3.6	101
93	Chronic expression of interferonâ€gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology, 2016, 64, 1189-1201.	3.6	93
94	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Scientific Reports, 2016, 6, 25906.	1.6	132
95	Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). Autoimmunity Reviews, 2016, 15, 795-800.	2.5	31
96	Diego and Giorgina Vergani: The two hearts of translational autoimmunity. Journal of Autoimmunity, 2016, 66, 1-6.	3.0	10
97	From old concerns to new advances and personalized medicine in lupus: The end of the tunnel is approaching. Journal of Autoimmunity, 2016, 74, 1-5.	3.0	15
98	Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. Journal of Autoimmunity, 2016, 75, 150-160.	3.0	48
99	Guillain-Barr \tilde{A} © syndrome: causes, immunopathogenic mechanisms and treatment. Expert Review of Clinical Immunology, 2016, 12, 1175-1189.	1.3	97
100	Environmental Basis of Autoimmunity. Clinical Reviews in Allergy and Immunology, 2016, 50, 287-300.	2.9	92
101	Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Review of Clinical Pharmacology, 2016, 9, 13-26.	1.3	51
102	Increased 5-hydroxymethylcytosine in CD4 \pm T cells in systemic lupus erythematosus. Journal of Autoimmunity, 2016, 69, 64-73.	3.0	110
103	Zika virus and neurologic autoimmunity: the putative role of gangliosides. BMC Medicine, 2016, 14, 49.	2.3	52
104	Adaptive immunity in the liver. Cellular and Molecular Immunology, 2016, 13, 354-368.	4.8	78
105	Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis. Expert Review of Clinical Immunology, 2016, 12, 661-672.	1.3	48
106	A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis. Expert Review of Molecular Diagnostics, 2016, 16, 697-705.	1.5	31
107	Evaluation of indeterminate biliary strictures. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 28-37.	8.2	99
108	AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis. Journal of Autoimmunity, 2016, 66, 89-97.	3.0	32

#	Article	IF	CITATIONS
109	Proposed therapies in primary biliary cholangitis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 371-382.	1.4	10
110	The clinical phenotypes of autoimmune hepatitis: A comprehensive review. Journal of Autoimmunity, 2016, 66, 98-107.	3.0	83
111	Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. Journal of Autoimmunity, 2016, 66, 40-50.	3.0	220
112	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS ONE, 2016, 11, e0159612.	1.1	23
113	Natural killer cells regulate T cell immune responses in primary biliary cirrhosis. Hepatology, 2015, 62, 1817-1827.	3.6	67
114	Chemokine (Câ€Xâ€C motif) ligand 13 promotes intrahepatic chemokine (Câ€Xâ€C motif) receptor 5+ lymphocythoming and aberrant Bâ€cell immune responses in primary biliary cirrhosis. Hepatology, 2015, 61, 1998-2007.	te 3.6	45
115	Innate Immunity Drives the Initiation of a Murine Model of Primary Biliary Cirrhosis. PLoS ONE, 2015, 10, e0121320.	1.1	19
116	IL-35 and Autoimmunity: a Comprehensive Perspective. Clinical Reviews in Allergy and Immunology, 2015, 49, 327-332.	2.9	78
117	Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review. Journal of Autoimmunity, 2015, 57, 1-13.	3.0	370
118	Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis. Journal of Autoimmunity, 2015, 59, 26-37.	3.0	45
119	Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. Journal of Autoimmunity, 2015, 63, 76-87.	3.0	30
120	The changing faces of IgG4-related disease: Clinical manifestations and pathogenesis. Autoimmunity Reviews, 2015, 14, 914-922.	2.5	41
121	Animal Models of Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2015, 48, 142-153.	2.9	55
122	The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis. American Journal of Clinical Pathology, 2015, 144, 601-606.	0.4	30
123	Lyme disease: A rigorous review of diagnostic criteria and treatment. Journal of Autoimmunity, 2015, 57, 82-115.	3.0	119
124	IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1284-1292.	0.5	76
125	The autoimmune basis of alopecia areata: A comprehensive review. Autoimmunity Reviews, 2015, 14, 81-89.	2.5	172
126	Animal Models of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 285-296.	1.8	46

#	Article	IF	CITATIONS
127	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. Frontiers in Immunology, 2014, 5, 128.	2.2	57
128	IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy. Hepatology, 2014, 59, 1944-1953.	3.6	168
129	The IL-23/IL-17 axis in psoriatic arthritis. Autoimmunity Reviews, 2014, 13, 496-502.	2.5	132
130	The diagnosis of primary biliary cirrhosis. Autoimmunity Reviews, 2014, 13, 441-444.	2.5	133
131	DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. Journal of Autoimmunity, 2014, 54, 127-136.	3.0	172
132	Diagnosis and classification of reactive arthritis. Autoimmunity Reviews, 2014, 13, 546-549.	2.5	157
133	Murine autoimmune cholangitis requires two hits: Cytotoxic KLRG1+ CD8 effector cells and defective T regulatory cells. Journal of Autoimmunity, 2014, 50, 123-134.	3.0	56
134	International consensus criteria for the diagnosis of Raynaud's phenomenon. Journal of Autoimmunity, 2014, 48-49, 60-65.	3.0	170
135	Antimitochondrial Antibody Recognition and Structural Integrity of the Inner Lipoyl Domain of the E2 Subunit of Pyruvate Dehydrogenase Complex. Journal of Immunology, 2013, 191, 2126-2133.	0.4	30
136	The Effect of Milk Components on the Immune Response to a Pneumonia Vaccine: A Randomized Placeboâ€controlled Clinical Trial. FASEB Journal, 2012, 26, 115.1.	0.2	0
137	Public safety and dietary supplementation. Annals of the New York Academy of Sciences, 2010, 1190, 104-117.	1.8	49
138	Infectious Agents and Xenobiotics in the Etiology of Primary Biliary Cirrhosis. Disease Markers, 2010, 29, 287-299.	0.6	38
139	Primary biliary cirrhosis. Hepatology, 2009, 50, 291-308.	3.6	1,020
140	The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology, 2008, 47, 737-745.	3.6	254
141	Reply:. Hepatology, 2008, 47, 1097-1097.	3.6	0
142	Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology, 2008, 48, 531-540.	3.6	167
143	Autoantibody Recognition of Functional Sites., 2006,, 473-491.		0
144	Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. Journal of Autoimmunity, 2005, 25, 126-132.	3.0	97

#	Article	IF	CITATIONS
145	Topics in Allergy and Immunology During Pregnancy and Early Infancy. Clinical Reviews in Allergy and Immunology, 2004, 26, 127-128.	2.9	0
146	Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology, 2003, 38, 1018-1025.	3.6	53
147	Identification of HLA-A2–restricted CD8+ Cytotoxic T Cell Responses in Primary Biliary Cirrhosis. Journal of Experimental Medicine, 2002, 195, 113-123.	4.2	278
148	Association of Single Nucleotide Polymorphisms of the Interleukin-10 Promoter Gene and Susceptibility to Primary Biliary Cirrhosis: Immunogenetic Differences in Italian and Japanese Patients. Autoimmunity, 2002, 35, 531-536.	1.2	16
149	Introduction. Clinical Reviews in Allergy and Immunology, 2002, 22, 205-206.	2.9	1
150	Quantitative and functional analysis of PDC-E2â€"specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. Journal of Clinical Investigation, 2002, 109, 1231-1240.	3.9	191
151	Quantitative and functional analysis of PDC-E2–specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. Journal of Clinical Investigation, 2002, 109, 1231-1240.	3.9	121
152	The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. Journal of Gastroenterology, 2001, 36, 248-254.	2.3	54
153	A case of autoimmune hepatitis with a high titer of antimitochondrial antibody and normal gamma-globulinemia. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 830-835.	1.4	5
154	Quantitative determination of ginsenosides by high-performance liquid chromatography-tandem mass spectrometry. Phytochemical Analysis, 2001, 12, 320-326.	1.2	85
155	Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: implications for pathogenesis. Journal of Pathology, 2001, 193, 102-109.	2.1	94
156	Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology, 2001, 33, 16-21.	3.6	219
157	Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: The molecule versus the mimic. Hepatology, 2001, 33, 792-801.	3.6	54
158	Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology, 2001, 34, 243-248.	3.6	185
159	Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: implications for pathogenesis., 2001, 193, 102.		1
160	Immunohistochemical analysis of cell-matrix adhesion molecules and their ligands in the portal tracts of primary biliary cirrhosis., 2000, 190, 93-99.		30
161	Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis. Hepatology, 2000, 31, 24-29.	3.6	82
162	Fetal microchimerisms in the mother: Immunologic implications. Liver Transplantation, 2000, 6, 138-143.	1.3	49

#	Article	IF	Citations
163	Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunological Reviews, 2000, 174, 210-225.	2.8	275
164	Fine Specificity of T Cells Reactive to Human PDC-E2 163-176 Peptide, the Immunodominant Autoantigen in Primary Biliary Cirrhosis: Implications for Molecular Mimicry and Cross-Recognition Among Mitochondrial Autoantigens. Hepatology, 2000, 32, 901-909.	3.6	67
165	Mucosal Immunity and Primary Biliary Cirrhosis: Presence of Antimitochondrial Antibodies in Urine. Hepatology, 2000, 32, 910-915.	3.6	69
166	Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2000, 18, 241-262.	2.9	1
167	Sick Building Syndrome. III. <i>Stachybotrys chartarum</i> . Journal of Asthma, 2000, 37, 191-198.	0.9	75
168	Autoimmune cholangitis and primary biliary cirrhosis? an autoimmune enigma. Liver International, 1999, 19, 122-128.	1.9	61
169	Use and abuse of intravenous immunoglobulin. Comprehensive Therapy, 1999, 25, 514-521.	0.2	0
170	Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology, 1999, 29, 1013-1018.	3.6	80
171	Generation of monoclonal antibodies to murine bile duct epithelial cells: Identification of annexin V as a new marker of small intrahepatic bile ducts. Hepatology, 1999, 29, 1019-1025.	3.6	23
172	In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1?, BCOADC-E1?, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis. Hepatology, 1999, 30, 36-45.	3.6	24
173	The immunobiology of bile and biliary epithelium. Hepatology, 1999, 30, 351-357.	3.6	117
174	Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. Hepatology, 1999, 30, 833-838.	3.6	111
175	The Pathogenesis of Osteonecrosis and the Relationships to Corticosteroids. Journal of Asthma, 1999, 36, 77-95.	0.9	99
176	Characterization of antimitochondrial antibodies in healthy adults. Hepatology, 1998, 27, 656-661.	3.6	136
177	Aly/Aly mice: A unique model of biliary disease. Hepatology, 1998, 27, 1499-1507.	3.6	9
178	Increased cd1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology, 1998, 28, 620-623.	3.6	103
179	Expression of co-stimulatory factor B7-2 on the intrahepatic bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis: an immunohistochemical study., 1998, 186, 126-130.		54
180	Immunity, infection, and nasal disease. Clinical Reviews in Allergy and Immunology, 1998, 16, 3-24.	2.9	3

#	Article	IF	Citations
181	Primary biliary cirrhosis. Immunologic Research, 1998, 18, 117-123.	1.3	6
182	Primary Biliary Cirrhosis an E pi thelitis: Evidence of Abnormal Salivary Gland Immunohistochemistry. Autoimmunity, 1997, 26, 23-31.	1.2	28
183	Food and Free Radicals. American Journal of Clinical Nutrition, 1997, 66, 1488.	2.2	0
184	Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver, 1997, 17, 281-287.	0.1	46
185	Risk Factors for Asthmatic Patients Requiring Intubation. III. Observations in Young Adults. Journal of Asthma, 1996, 33, 27-35.	0.9	46
186	Granulomatous cholangitis in chronic hepatitis C: A new diagnostic problem in liver pathology. Pathology International, 1996, 46, 301-305.	0.6	16
187	Risk Factors for Intubation of Adult Asthmatic Patients. Journal of Asthma, 1995, 32, 97-104.	0.9	7
188	Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology, 1995, 21, 113-119.	3.6	111
189	Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology, 1995, 21, 1031-1037.	3.6	97
190	Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology, 1995, 22, 505-513.	3.6	86
191	Immunohistochemical analysis of adhesion molecules in the micro-environment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. Journal of Pathology, 1995, 175, 319-325.	2.1	77
192	Elevated serum silicon levels in women with silicone gel breast implants. Biological Trace Element Research, 1995, 48, 121-130.	1.9	31
193	Intestinal Immunology and Food Allergy. American Journal of Clinical Nutrition, 1995, 62, 1029-1030.	2.2	0
194	Risk Factors for Asthmatic Patients Requiring Intubation. I. Observations in Children. Journal of Asthma, 1995, 32, 285-294.	0.9	77
195	Animal Models of Scleroderma: Contrasts and Comparisons. International Reviews of Immunology, 1995, 12, 201-216.	1.5	20
196	The Immunologic and Genetic Basis of Avian Scleroderma, an Inherited Fibrotic Disease of Line 200 Chickens. International Reviews of Immunology, 1994, 11, 273-282.	1.5	5
197	Heterogeneity of combinatorial human autoantibodies against PDC-E2 and biliary epithelial cells in patients with primary biliary cirrhosis. Hepatology, 1994, 20, 574-583.	3.6	44
198	Human combinatorial autoantibodies and mouse monoclonal antibodies to PDC-E2 produce abnormal apical staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sjogren's syndrome. Hepatology, 1994, 20, 893-898.	3.6	44

#	Article	IF	Citations
199	An autoantigen in PSC? Whither or whether? Mandal A, Dasgupta A, Jeffers L, Squillante L, Hyder S, Reddy R, Schiff E, Das KM. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology 1994;106:185–192. Hepatology, 1994, 20, 1096-1098.	3.6	1
200	Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis: Applications of a semiautomated assay. Hepatology, 1994, 20, 1220-1224.	3.6	32
201	Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens, 1994, 43, 71-77.	1.0	79
202	Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis: Applications of a semiautomated assay. Hepatology, 1994, 20, 1220-1224.	3.6	3
203	The use of the clinical immunology laboratory. Clinical Reviews in Allergy, 1994, 12, 125-149.	1.0	1
204	B-1a and conventional B cells from autoimmune NZB. H-2bm12 mice exhibit similar functional characteristics in vivo. European Journal of Immunology, 1993, 23, 1866-1871.	1.6	7
205	Chromosome Localization and Rflp Analysis of Pdc-E2: the Major Autoantigen of Primary Biliary Cirrhosis. Autoimmunity, 1993, 14, 335-340.	1.2	7
206	Phenotypic Analysis of the Chicken Thymic Microenvironment During Ontogenic Development. Autoimmunity, 1992, 2, 19-27.	0.6	10
207	Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: Antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology, 1992, 16, 899-905.	3.6	33
208	M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena?. Hepatology, 1992, 16, 1128-1136.	3.6	67
209	M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena?. Hepatology, 1992, 16, 1128-1136.	3.6	10
210	Overview of proceedings. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 554-557.	1.4	0
211	Molecular characterization of the mitochondrial autoantigens in primary biliary cirrhosis. Immunologic Research, 1991, 10, 518-527.	1.3	24
212	lonic Binding Characteristics of Monoclonal Autoantibodies to DNA from NZB.H-2 ^{bm12} Mice. Autoimmunity, 1991, 9, 301-309.	1.2	6
213	The Contribution Of I-Abm12To The Production Of Autoantibodies To dsDNA. Autoimmunity, 1991, 11, 81-88.	1.2	0
214	Genetic control of avian scleroderma. Immunogenetics, 1990, 31, 291-295.	1.2	16
215	The relative affinity of recombinant dihydrolipoamide transacetylase for autoantibodies in primary biliary cirrhosis. Hepatology, 1990, 11, 717-722.	3.6	12
216	Inhibition of α-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis. Hepatology, 1990, 11, 975-981.	3.6	72

#	Article	IF	CITATIONS
217	Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis. Hepatology, 1990, 12, 306-313.	3.6	114
218	Site-directed mutagenesis of lysine within the immunodominant autoepitope of PDC-E2. Hepatology, 1990, 12, 1321-1328.	3.6	54
219	Cellular Immune Response of SIVâ€Infected Rhesus Macaques. Journal of Medical Primatology, 1990, 19, 177-187.	0.3	9
220	Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched-chain α-keto acid dehydrogenase dihydrolipoamide acyltransferase, the 52 kD mitochondrial autoantigen. Hepatology, 1989, 9, 63-68.	3.6	120
221	Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology, 1989, 9, 411-416.	3.6	108
222	Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. Hepatology, 1989, 10, 127-133.	3.6	127
223	Identification of t cells in early dermal lymphocytic infiltrates in avian scleroderma. Arthritis and Rheumatism, 1989, 32, 1031-1040.	6.7	32
224	Autoantibodies to mitochondria in systemic sclerosis. frequency and characterization using recombinant cloned autoantigen. Arthritis and Rheumatism, 1988, 31, 386-392.	6.7	43
225	Primary biliary cirrhosis and mitochondrial autoantigensâ€"insights from molecular biology. Hepatology, 1988, 8, 147-151.	3.6	103
226	The effect of variable magnesium intake on potential factors influencing endurance capacity. Biological Trace Element Research, 1988, 16, 1-18.	1.9	8
227	Serial observations and definition of mononuclear cell infiltrates in avian scleroderma, an inherited fibrotic disease of chickens. Arthritis and Rheumatism, 1984, 27, 807-815.	6.7	38
228	Trace Metals, Aging, and Immunity. Journal of the American Geriatrics Society, 1983, 31, 374-378.	1.3	15
229	Clonal proliferation of peritoneal exudate cells from New Zealand black mice: Age-related changes. The Anatomical Record, 1982, 204, 209-214.	2.3	1
230	Therapy for Nb rat tumor transplanted in athymic mice. Journal of Surgical Oncology, 1981, 16, 265-272.	0.8	1
231	Combination chemotherapy in a prostate tumor model: Nb rat prostatic adenocarcinoma model. Journal of Surgical Oncology, 1981, 16, 353-363.	0.8	5
232	Zinc, Copper, and Manganese in immune function and experimental oncogenesis. Nutrition and Cancer, 1981, 3, 172-191.	0.9	35
233	Growth and Development in Postnatally Zinc-Deprived Mice. Journal of Nutrition, 1980, 110, 201-211.	1.3	50
234	Influence of Dietary Fat Concentration and Saturation on Immune Ontogeny in Mice. Journal of Nutrition, 1980, 110, 1555-1572.	1.3	81

#	Article	IF	CITATIONS
235	Study of thymic factors. II. Failure of thymosin to alter the natural history of nzb and nzb/nzw mice. Arthritis and Rheumatism, 1976, 19, 862-866.	6.7	28
236	Increased Frequency of HLâ€A8 in Sjogren's Syndrome. Tissue Antigens, 1975, 6, 342-346.	1.0	47